Skip to main content
Top
Published in: BMC Urology 1/2023

Open Access 01-12-2023 | Metformin | Research

Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada

Authors: Michel D. Wissing, Ana O’Flaherty, Alice Dragomir, Simon Tanguay, Wassim Kassouf, Armen G. Aprikian

Published in: BMC Urology | Issue 1/2023

Login to get access

Abstract

Background

Studies have suggested a positive association between bladder cancer (BC) outcome and comedication use, including nonsteroidal anti-inflammatory drugs (NSAID), metformin, and prednisone use. To validate these associations, we evaluated whether these medications were associated with clinical outcome in a Canadian cohort of BC patients.

Methods

This is a retrospective cohort study on BC patients undergoing radical cystectomy (RC) in Québec province in 2000–2015, as registered in the provincial health administration databases. Medication use was considered chronic when prescribed for ≥ 1 year. Overall (OS), disease-specific (DSS) and recurrence-free (RFS) survival were compared using multivariable Cox proportional hazards models. Covariates included age, Charlson’s comorbidity index, region of residence, year of RC, distance to hospital, hospital type, hospital and surgeon annual RC volume, neoadjuvant chemotherapy use, and type of bladder diversion, as well as mutual adjustment for concomitant comedication use (statins, NSAIDs, metformin, and prednisone).

Results

Of 3742 patients included, 293, 420, and 1503 patients chronically used prednisone, metformin, and NSAIDs before surgery, respectively. In multivariable analyses, preoperative prednisone use was associated with improved OS (HR 0.67, 95%CI 0.55–0.82), DSS (HR 0.58, 95%CI 0.45–0.76), and RFS (HR 0.61, 95%CI 0.47–0.78). Patients who chronically used metformin preoperatively had a worse OS (HR 1.29, 95%CI 1.07–1.55), DSS (HR 1.38, 95%CI 1.10–1.72), and RFS (HR 1.41, 95%CI 1.13–1.74). Preoperative, chronic NSAID use was not significantly associated with all clinical outcomes, with adjusted HRs for OS, DSS, and RFS of 1.10 (95%CI 0.95–1.27), 1.24 (95%CI 1.03–1.48), and 1.22 (95%CI 1.03–1.45), respectively. Directionality of findings was similar when stratifying by comedication use in the year following surgery. Results were similar after propensity-score matching too.

Conclusions

In our Canadian cohort of BC undergoing RC, chronic prednisone use was associated with improved clinical outcomes, while metformin and NSAID were not.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA Cancer J Clin. 2021;71(1):7–33. Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA Cancer J Clin. 2021;71(1):7–33.
3.
go back to reference Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):177–89. vii.CrossRefPubMed Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):177–89. vii.CrossRefPubMed
4.
go back to reference Wissing MD, Santos F, Zakaria AS, O’Flaherty A, Tanguay S, Kassouf W et al. Short- and long-term survival has improved after radical cystectomy for bladder cancer in Quebec during the years 2000–2015. J Surg Oncol. 2019. Wissing MD, Santos F, Zakaria AS, O’Flaherty A, Tanguay S, Kassouf W et al. Short- and long-term survival has improved after radical cystectomy for bladder cancer in Quebec during the years 2000–2015. J Surg Oncol. 2019.
5.
go back to reference Wissing MD, O’Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. Statins are Associated with reduced overall and Cancer-specific mortality in patients undergoing radical cystectomy for bladder Cancer. Bladder Cancer. 2020;6:53–62.CrossRef Wissing MD, O’Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. Statins are Associated with reduced overall and Cancer-specific mortality in patients undergoing radical cystectomy for bladder Cancer. Bladder Cancer. 2020;6:53–62.CrossRef
6.
go back to reference Wissing MD, O’Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. The Use of 5-Alpha reductase inhibitors and Alpha-1 blockers does not improve clinical outcome in male patients undergoing radical cystectomy for bladder Cancer in Quebec, Canada. Clinical genitourinary cancer. 2021. Wissing MD, O’Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. The Use of 5-Alpha reductase inhibitors and Alpha-1 blockers does not improve clinical outcome in male patients undergoing radical cystectomy for bladder Cancer in Quebec, Canada. Clinical genitourinary cancer. 2021.
7.
go back to reference Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, et al. The Association of Aspirin Use with Survival following radical cystectomy. J Urol. 2018;200(5):1014–21.CrossRefPubMed Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, et al. The Association of Aspirin Use with Survival following radical cystectomy. J Urol. 2018;200(5):1014–21.CrossRefPubMed
8.
go back to reference Pastore A, Palleschi G, Fuschi A, Silvestri L, Al Salhi Y, Costantini E, et al. Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. BMC Cancer. 2015;15:120.CrossRefPubMedPubMedCentral Pastore A, Palleschi G, Fuschi A, Silvestri L, Al Salhi Y, Costantini E, et al. Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. BMC Cancer. 2015;15:120.CrossRefPubMedPubMedCentral
9.
go back to reference Hu J, Chen JB, Cui Y, Zhu YW, Ren WB, Zhou X, et al. Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Medicine. 2018;97(30):e11596.CrossRefPubMedPubMedCentral Hu J, Chen JB, Cui Y, Zhu YW, Ren WB, Zhou X, et al. Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Medicine. 2018;97(30):e11596.CrossRefPubMedPubMedCentral
10.
go back to reference Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184–95.CrossRefPubMedPubMedCentral Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184–95.CrossRefPubMedPubMedCentral
11.
go back to reference Bosetti C, Rosato V, Gallus S, La Vecchia C. Aspirin and urologic cancer risk: an update. Nat reviews Urol. 2012;9(2):102–10.CrossRef Bosetti C, Rosato V, Gallus S, La Vecchia C. Aspirin and urologic cancer risk: an update. Nat reviews Urol. 2012;9(2):102–10.CrossRef
12.
go back to reference Emilsson L, Garcia-Albeniz X, Logan RW, Caniglia EC, Kalager M, Hernan MA. Examining Bias in Studies of Statin Treatment and Survival in patients with Cancer. JAMA Oncol. 2018;4(1):63–70.CrossRefPubMed Emilsson L, Garcia-Albeniz X, Logan RW, Caniglia EC, Kalager M, Hernan MA. Examining Bias in Studies of Statin Treatment and Survival in patients with Cancer. JAMA Oncol. 2018;4(1):63–70.CrossRefPubMed
13.
go back to reference de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRefPubMedPubMedCentral de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRefPubMedPubMedCentral
14.
go back to reference de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.CrossRefPubMed de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.CrossRefPubMed
15.
go back to reference Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMed Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMed
16.
go back to reference Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol. 2006;13(6):3335–9.PubMed Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol. 2006;13(6):3335–9.PubMed
17.
go back to reference Vitanza NA. 50 years ago in TheJournal ofPediatrics: induction of Remission in Acute Leukemia of Childhood by Combination of Prednisone and either 6-Mercaptopurine or methotrexate. J Pediatr. 2016;173:100.CrossRefPubMed Vitanza NA. 50 years ago in TheJournal ofPediatrics: induction of Remission in Acute Leukemia of Childhood by Combination of Prednisone and either 6-Mercaptopurine or methotrexate. J Pediatr. 2016;173:100.CrossRefPubMed
18.
go back to reference Ide H, Inoue S, Miyamoto H. The role of glucocorticoid receptor signaling in bladder Cancer progression. Cancers (Basel). 2018;10(12). Ide H, Inoue S, Miyamoto H. The role of glucocorticoid receptor signaling in bladder Cancer progression. Cancers (Basel). 2018;10(12).
19.
go back to reference Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.CrossRefPubMed Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.CrossRefPubMed
20.
go back to reference Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef
21.
go back to reference Cox DR. Regression models and life-tables. J Royal Stat Soc Ser B (Methodological). 1972;34(2):187–220. Cox DR. Regression models and life-tables. J Royal Stat Soc Ser B (Methodological). 1972;34(2):187–220.
22.
go back to reference Wissing MD, Kassouf W, Tanguay S, Aprikian AG. The use of perioperative chemotherapy in patients undergoing radical cystectomy for bladder cancer in Quebec, Canada, 2000–2016. Can Urol Assoc J. 2020;14(5):E191–e201.PubMed Wissing MD, Kassouf W, Tanguay S, Aprikian AG. The use of perioperative chemotherapy in patients undergoing radical cystectomy for bladder cancer in Quebec, Canada, 2000–2016. Can Urol Assoc J. 2020;14(5):E191–e201.PubMed
23.
go back to reference Dietrich K, Schned A, Fortuny J, Heaney J, Marsit C, Kelsey KT, et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer. 2009;101(8):1316–20.CrossRefPubMedPubMedCentral Dietrich K, Schned A, Fortuny J, Heaney J, Marsit C, Kelsey KT, et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer. 2009;101(8):1316–20.CrossRefPubMedPubMedCentral
24.
go back to reference Ishiguro H, Kawahara T, Zheng Y, Kashiwagi E, Li Y, Miyamoto H. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemother Pharmacol. 2014;74(2):249–55.CrossRefPubMed Ishiguro H, Kawahara T, Zheng Y, Kashiwagi E, Li Y, Miyamoto H. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemother Pharmacol. 2014;74(2):249–55.CrossRefPubMed
25.
go back to reference Li P, Chen J, Miyamoto H. Androgen receptor signaling in bladder Cancer. Cancers (Basel). 2017;9(2). Li P, Chen J, Miyamoto H. Androgen receptor signaling in bladder Cancer. Cancers (Basel). 2017;9(2).
26.
27.
go back to reference Zhang W, Wang R, Ma W, Wu Y, Maskey N, Guo Y, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. Ann Transl Med. 2019;7(18):431.CrossRefPubMedPubMedCentral Zhang W, Wang R, Ma W, Wu Y, Maskey N, Guo Y, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. Ann Transl Med. 2019;7(18):431.CrossRefPubMedPubMedCentral
28.
go back to reference Yeh HC, Golozar A, Brancati FL. Cancer and Diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, et al. editors. Diabetes in America. Bethesda (MD) interest. National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018. Yeh HC, Golozar A, Brancati FL. Cancer and Diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, et al. editors. Diabetes in America. Bethesda (MD) interest. National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.
29.
go back to reference Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, Schatzkin A, et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol. 2011;173(7):721–30.CrossRefPubMedPubMedCentral Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, Schatzkin A, et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol. 2011;173(7):721–30.CrossRefPubMedPubMedCentral
30.
go back to reference Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. BJU Int. 2009;103(6):736–9.CrossRefPubMed Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. BJU Int. 2009;103(6):736–9.CrossRefPubMed
32.
go back to reference Liu Q, Yuan W, Tong D, Liu G, Lan W, Zhang D, et al. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget. 2016;7(19):28235–46.CrossRefPubMedPubMedCentral Liu Q, Yuan W, Tong D, Liu G, Lan W, Zhang D, et al. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget. 2016;7(19):28235–46.CrossRefPubMedPubMedCentral
Metadata
Title
Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada
Authors
Michel D. Wissing
Ana O’Flaherty
Alice Dragomir
Simon Tanguay
Wassim Kassouf
Armen G. Aprikian
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2023
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-023-01287-6

Other articles of this Issue 1/2023

BMC Urology 1/2023 Go to the issue